In a recent article published in Future Science OA, medical advisors from the K-DETEK study presented a guideline-based post-test standard operating procedure (SOP) and six clinical cases. These cases clearly demonstrate how SPOT-MAS test can deliver effective results in early cancer screening with a structured pathway, thereby guiding follow-up diagnostics and ensuring clarity for both patients and healthcare providers.
This publication highlights the benefits of performing multi-cancer early detection (MCED) in clinical practice using a standard SOP, including:
- Early-stage cancer detection: MCED has the potential to detect cancers at very early stages, even before clinical symptoms appear, consequently improving treatment outcomes.
- Accurate follow-up process: With a standardized SOP, the steps from detecting a positive ctDNA signal to using imaging and biopsy for confirmation are conducted systematically, avoiding unnecessary interventions and ensuring timely treatment decisions.
- Effective across targeted cancer types: SPOT-MAS has proven effective in detecting multiple common cancers, such as liver, lung, breast, colorectum, and stomach cancers. This not only aids in detection but also improves patient management throughout diagnosis and early interventions.
In summary, the SPOT-MAS R&D team shows that MCED is a highly practical method for early cancer detection when applied with a standardized protocol in clinical settings.
For a detailed look at this research, please refer to our blog here: https://spotmas.com/blog/effective-clinical-follow-up-for-ctdna-multi-cancer-early-detection-test-a-peer-reviewed-study-of-post-test-standard-operating-procedure-and-real-life-results/
#CancerResearch #EarlyDetection #OncologyInnovation #GeneSolutions #ctDNA #SPOTMAS #MCED #MulticancerEarlyDetection
